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Abstract
Background: Factor V Leiden (FVL) and prothrombin gene mutation (PGM) are common inherited thrombophilias.
Retrospective studies variably suggest a link between maternal FVL/PGM and placenta-mediated pregnancy complications
including pregnancy loss, small for gestational age, pre-eclampsia and placental abruption. Prospective cohort studies
provide a superior methodologic design but require larger sample sizes to detect important effects. We undertook a
systematic review and a meta-analysis of prospective cohort studies to estimate the association of maternal FVL or PGM
carrier status and placenta-mediated pregnancy complications.
Methods and Findings: A comprehensive search strategy was run in Medline and Embase. Inclusion criteria were: (1)
prospective cohort design; (2) clearly defined outcomes including one of the following: pregnancy loss, small for gestational
age, pre-eclampsia or placental abruption; (3) maternal FVL or PGM carrier status; (4) sufficient data for calculation of odds
ratios (ORs). We identified 322 titles, reviewed 30 articles for inclusion and exclusion criteria, and included ten studies in the
meta-analysis. The odds of pregnancy loss in women with FVL (absolute risk 4.2%) was 52% higher (OR=1.52, 95%
confidence interval [CI] 1.06–2.19) as compared with women without FVL (absolute risk 3.2%). There was no significant
association between FVL and pre-eclampsia (OR=1.23, 95% CI 0.89–1.70) or between FVL and SGA (OR=1.0, 95% CI 0.80–
1.25). PGM was not associated with pre-eclampsia (OR=1.25, 95% CI 0.79–1.99) or SGA (OR 1.25, 95% CI 0.92–1.70).
Conclusions: Women with FVL appear to be at a small absolute increased risk of late pregnancy loss. Women with FVL and
PGM appear not to be at increased risk of pre-eclampsia or birth of SGA infants.
Please see later in the article for the Editors’ Summary.
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Pregnancy loss, pre-eclampsia, small for gestational age (SGA)
pregnancies, and placental abruption are distressing and often
devastating pregnancy outcomes for women, their families, and
society [1–3]. Frequently occurring as a result of placental
insufficiency, they affect more than one in 20 pregnancies [3,4].
Thrombophilia describes an increased tendency to develop
thrombosis, either venous or arterial. Thrombophilias may either
be inherited or acquired and include protein C deficiency, protein
S deficiency, antithrombin deficiency, and the less potent factor V
Leiden (FVL) and prothrombin gene mutation (PGM). The
combined prevalence of these thrombophilias in the general
population exceeds one in ten [5–11]. A successful pregnancy
requires the development of adequate placental circulation. It is
hypothesised that thrombophilias may increase the risk of
placental insufficiency because of placental micro- and/or
macro-vascular thrombosis, as well as effects on trophoblast
growth and differentiation [12].
Individual case control studies variably demonstrate an
association between the placenta-mediated pregnancy complica-
tions and thrombophilia but when meta-analysed suggest a weak
positive association [13–15]. Case control studies are limited by (1)
retrospective data collection leading to potential bias in outcome
classification and incomplete and/or poor confounder data
acquisition and (2) possible differential participation bias where
more severe cases are recruited. Prospective cohort studies limit
these potential biases but have limited power to detect weak
associations [16]. Prospective cohort studies also provide absolute
risk estimates that can be used to counsel patients. Our objective
was to undertake a systematic review and a meta-analysis of
prospective cohort studies to estimate the risk of these common
and important placenta-mediated pregnancy complications in the
women with and without FVL or PGM.
Methods
Search Strategy
Following our systematic review protocol, a systematic literature
search strategy was conducted to identify potential studies in
MEDLINE (1950 to November 2007) and EMBASE (1980 to
November 2007) using the OVID interface. The search was
updated in February 2010.We identified the following relevant
MeSH and free terms for the exposures and outcomes by literature
review and by recommendations from experts in the field (MAR,
MC): Thrombophilia, activated protein C resistance (APCR),
FVL, and PGM (PGM, PGV, G202110A, G1691A) for the
exposure. For the outcome we used the subject headings
pregnancy complications, abruption placentae, abortion sponta-
neous, stillbirth, pre-eclampsia, HELLP syndrome, hypertension-
pregnancy induced, fetal growth retardation, low birth weight, and
the free term miscarriage. Different subject headings were used for
EMBASE or MEDLINE when appropriate. These searches were
limited to observational studies by applying validated filters for
MEDLINE and EMBASE available in the Scottish Intercollegiate
Guidelines Network [17]. The search was also restricted to
humans. There were no restrictions on language, publication year,
or type of publication. Our full systematic search strategy is
documented in Table S1. In addition to the electronic search, we
examined reference lists of retrieved articles and identified
additional articles and abstracts from recommendations of experts
in the field. Duplicate reports of the same cohort reporting the
same outcomes with the same exposures were excluded. Records
of selected articles were examined by two independent reviewers
(MTB and MAR) to identify all relevant citations.
Selection Criteria
Using a structured question format to aid our literature search
strategy, we reviewed all potentially relevant articles that satisfied
all of the following criteria: (1) unselected pregnant women
enrolled prospectively in the first or second trimester of pregnancy;
(2) women investigated for FVL (diagnosed by DNA-based PCR
assay for FVL mutation) or PGM (by DNA-based PCR assay)
carrier status (homozygotes, heterozygotes, or both); and (3)
reported any of the following placenta-mediated pregnancy
complication outcomes: pregnancy loss, pre-eclampsia, placenta
abruption, or SGA.
Outcome Measures
The primary outcome measure was the incidence of placenta-
mediated complications during pregnancy (pregnancy loss, pre-
eclampsia, SGA, and placental abruption). Pre-eclampsia was
defined as systolic blood pressure of 140 mm Hg or higher or a
diastolic blood pressure of 90 mm Hg or higher occurring after
20 wk of gestation in a woman whose blood pressure has
previously been normal; plus proteinuria, with excretion of 0.3 g
or more of protein in a 24-h urine specimen or proteinuria $2b y
dipstick [18,19]. Pregnancy loss included (1) spontaneous miscar-
riage (involuntary termination of pregnancy before 20 wk of
gestation, dated from the last menstrual period) or below a fetal
weight of 500 g [20,21] and (2) stillbirth (complete expulsion or
extraction of a dead fetus at or after 20 wk of pregnancy, or when
the fetal weight was at least 500 g in cases where the gestational
age is not known) [22]. Placental abruption was defined as ante
partum retroplacental, marginal, or preplacental hemorrhage
confirmed by imaging studies or visual inspection of the placenta
[23]. SGA was defined as a birth weight less than 10th percentile
of population-specific birth weight adjusted for gender and
gestational age. Severe SGA was defined as a birth weight less
than 5th percentile of population-specific gender and gestational
age-adjusted birth weight [24,25].
Data Extraction and Quality Assessment
Two reviewers (MTB and MAR) independently applied the
inclusion criteria to the identified articles from the initial search
strategy. Articles for potential full review were discussed
between the two reviewers. A data-extraction form was
designed, piloted, and revised. Reviewers independently ex-
tracted baseline characteristics of the included studies and
obtained a 262 table with the number of placenta-mediated
complications in exposed and unexposed patients (i.e., FVL or
PGM status). The corresponding authors of studies with missing
data were contacted. Discrepancies were noted and discussed
between reviewers. Adjudication by a third party to resolve
conflicts was not necessary.
The methodological quality of the studies was evaluated using
the validated Newcastle–Ottawa scale (NOS) for prospective
cohort studies as recommended by the Cochrane Non-Random-
ized Studies Methods Working Group [26]. The quality of a
study was judged on the selection of the study groups, the
comparability of the groups, and the ascertainment of the
outcome of interest. For all eligible studies, two reviewers (MTB
and MAR) independently assessed study quality and extracted the
data using a standardized data abstraction form. Likewise, any
discrepancies were documented and discussed between the
reviewers.
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We chose to use the pooled estimate of the odds ratio (OR) as
our measure of effect, to analyze the results based on 95%
confidence intervals (CIs), and to report two-sided p-values.
Statistical heterogeneity between and within groups was measured
using I
2 statistic [27]. I
2,25% was considered low heterogeneity,
25%–50% was moderate heterogeneity, and .50% was consid-
ered high heterogeneity [28]. We used Mantel-Haenszel analysis
with 0.5 zero cell replacement method for this meta-analysis given
event rates over 1% for the placenta-mediated pregnancy
complications, imbalance in exposed/nonexposed groups, and
imbalance in cases and controls [29]. In sensitivity analyses Peto
ORs were also determined. Fixed-effect method was used to pool
results for all models. We used sensitivity analysis to explore the
causes of heterogeneity and to determine the impact that
differences in outcome definition or measurement had on our
results [30]. We also planned to examine funnel plots to assess
publication bias if sufficient number of studies were included to
permit assessment of publication bias.
The analysis was conducted using SAS 9.1 and RevMan 5.0
software from the Cochrane reviews.
Results
A total of 322 articles and one abstract (see Figure 1 for study
selection flowchart) were identified. Of these, 95 were deemed
relevant on the basis of their title. After abstract review, 30 articles
and one abstract were selected for full article review or direct data
retrieval from the authors. Of the 30 studies, 12 studies did not
meet the inclusion criteria, and eight studies did not have sufficient
data for inclusion after full article review. After contacting authors,
we obtained data on the number of events and study design
features for one of the eight published articles with insufficient data
for this review [31]. We also obtained complete data for the
abstract [32]. After reviewing the full text of the papers and
contacting the authors we included ten articles in the review [31–
40]. We did not exclude any study on the basis of the definition of
outcome used by the authors.
Included Studies Characteristics
The association between thrombophilias (FVL or PGM) and
placenta-mediated pregnancy complications was summarized
from ten prospective cohort studies. Of the included studies, there
were cohorts from Dublin, Ireland [38]; Tel Aviv, Israel [31];
multiple centers in the United States, which gave rise to two
publications, one reporting on FVL thrombophilia [34] and one
reporting on PGM thrombophilia [40]; Glasgow, UK [33]; Avon,
UK [35]; Melbourne, Australia [39]; Patras, Greece [36]; Malmo,
Sweden [37] and Ottawa, Canada [32].
The characteristics of the selected studies are summarized in
Table 1 and Table S2. The cohorts were homogeneous and
consistent in terms of participants, exposures, and outcomes except
for the outcomes of pregnancy loss and placental abruption. The
latter definitions were either unclear and/or inconsistent across
studies. Participants were women with spontaneous singleton
pregnancy in either their first or second trimester except for one
study where all patients were enrolled before 8 wk of gestation
[36] and one study where a small number of multiple pregnancies
were included [39]. Gestational age at enrollment ranged from 6
to 22 wk and most women were under 35 y of age. We were not
able to find information on gestational age at enrollment for one
study [35]. FVL prevalence (either homozygous or heterozygote)
varied across selected studies from 2.7% [38] to 10.9% [37].
The quality of the included studies as assessed using the
Newcastle–Ottawa quality assessment scales scored high in
selection and comparability of the study groups as well as in
ascertainment of the outcome of interest (see Table 1).
The limited number of studies included in our meta-analysis did
not permit assessment of publication bias.
Maternal FVL/PGM and Pregnancy Loss
We identified seven studies reporting information on pregnancy
loss [32–34,36–39]. Most studies included patients with sponta-
neous miscarriage or stillbirth as pregnancy losses but there were
important inconsistencies in the definition of this outcome. The
pooled OR estimate from these seven studies is 1.52 (95% CI
1.06–2.19) in 16,959 total women with an observed FVL
prevalence of 4.7% (see Figure 2). The absolute risk of pregnancy
loss in women with FVL was 4.2% as compared with 3.2% for
FVL negative women.
A fixed effect model was used for assessment of pregnancy loss
despite substantial statistical heterogeneity across studies
(I
2=51%, p=0.06). The pooled estimate remained statistically
significant when a random effect model was used 1.96 (95% CI
1.13–3.38) or when we used a Peto OR fixed model 1.64 (1.07–
2.51). We suspected that differences in the definition of pregnancy
loss across studies was the most likely explanation for this
heterogeneity (see Table S2). Heterogeneity was significantly
reduced when the two studies that included either spontaneous
abortion only [38] or stillbirth only [39] were removed from the
pooled analysis (I
2=15%, p=0.32). After removing these two
studies the pooled OR was no longer significant at 1.34 (95% CI
0.90–1.98). In addition, most studies enrolled both primiparous or
multiparous women except the aforementioned two studies
[38,39], which included primiparous women only.
There were four studies reporting on the association of PGM
and pregnancy loss with a pooled OR estimate of 1.13 and wide
95% CIs (0.64–2.01) (see Figure 3).
Maternal FVL/PGM and Pre-eclampsia
All ten selected studies reported information on pre-eclampsia.
The presence of FVL mutation did not significantly increase the
risk of pre-eclampsia, with a pooled OR estimate of 1.23 (95% CI
0.89–1.70) in 21,833 total women with a FVL prevalence of 4.9%
(see Figure 2). The absolute risk of pre-eclampsia in FVL positive
women was 3.8% as compared with 3.2% for FVL-negative
women. There was no statistical heterogeneity across studies and
the definition of the outcome pre-eclampsia was fairly consistent
across the studies (see Table S2).
The combination of six studies reporting on PGM status and
pre-eclampsia did not show significant association between PGM
(heterozygous or homozygous) and pre-eclampsia with a pooled
OR=1.25 (95% CI 0.79–1.99) in 14,254 total women with a
PGM prevalence of 4.1%.(see Figure 3). The absolute risk of pre-
eclampsia in women with PGM was 3.5% as compared with 3.0%
for PGM negative women.
Maternal FVL/PGM and SGA Neonate (Birth Weight
,10th Percentile)
There were seven studies reporting information on SGA and
FVL [31,32,34,35,37–39]. All studies had a fairly homogeneous
definition of SGA although some heterogeneity may have been
introduced by three studies that used country-specific birth-weight
standardized charts (see Table S2) [32,35,39]. The presence of
FVL did not significantly increase the risk of SGA, with a pooled
OR estimate of 1.0 (95% CI 0.80–1.25) in 20,654 total women
FVL and PGM and PMP Complications
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SGA ,10th percentile in women with FVL was 6.5% as
compared with 7.4% for FVL-negative women. This lack of
association did not vary after exclusion of the three studies that
used country-specific birth-weight charts (OR=0.91, 95% CI
0.64–1.28) [32,35,39].
Five studies reported PGM status and SGA ,10th percentile
[31,32,35,39,40] in 17,287 total women with a PGM prevalence of
5.1%. The absolute risk of SGA ,10th percentile in women with
PGM (heterozygous or homozygous) was 5.4% as compared with
5.7% for PGM negative women. We did not find a significant
association between PGM (heterozygous or homozygous) and
SGA ,10th percentile (pooled OR=1.25, 95% CI 0.92–1.70) (see
Figure 3).
Maternal FVL/PGM and Severe SGA Neonate (Birth
Weight ,5th Percentile)
Five studies reported FVL status and birth weight under 5th
percentile [33,34,36,37,39,41,42] with a total of 12,936 women,
FVL prevalence 4.9%. The absolute risk of SGA ,5th percentile
Figure 1. Study selection.
doi:10.1371/journal.pmed.1000292.g001
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women FVL negative. The combined OR for this population
showed no significant association between FVL status and SGA
,5th percentile (pooled OR=0.92, 95% CI 0.61–1.40). The
pooled OR estimate of three studies reporting on SGA ,5th
percentile and PGM was 1.46 (0.81–2.62) in 6,285 total women
with a prevalence of 3.3% for PGM. The prevalence of SGA ,5th
percentile in women with PGM was 5.7% as compared with 4.3%
for PGM negative women.
Maternal FVL/PGM and Placental Abruption
There were five studies reporting the association between FVL
mutation and placenta abruption [32,34,36,37,39]. These studies
included 12,308 women with a pooled FVL prevalence of 5.1%.
The absolute risk of placenta abruption in FVL positive women
was 1.3% as compared with 0.9% for FVL negative women. The
pooled OR estimate for placental abruption in women with FVL
mutation (homozygous or heterozygous) was 1.85 (95% CI 0.92–
3.70) (see Figure 2). The moderate statistical heterogeneity with
I
2=33% may be attributable to the inconsistent and unclear
definition of placental abruption across studies (see Table 1).
The pooled OR estimate for placental abruption in women with
PGM mutation (homozygous or heterozygous) was 2.02 (95% CI
0.81–5.02) with moderate heterogeneity across studies (I
2=49%)
(see Figure 3).
The results for all four individual outcomes were not
substantially different in sensitivity analysis using Peto ORs.
Maternal FVL/PGM and the Composite of Any Placenta-
Mediated Pregnancy Complications
There was no association between FVL and the composite
outcome of any of the placenta-mediated pregnancy complications
(pregnancy loss, placental abruption, pre-eclampsia, and SGA
[.10th percentile]) with a pooled OR=1.08 (95% CI 0.87–1.52)
from four studies reporting on the four outcomes (see Figure 4).
There was no association between PGM and the composite
outcome of any placenta-mediated pregnancy complications
(pregnancy loss, placental abruption, pre-eclampsia, and SGA
[.10
th percentile]) with a pooled OR=1.27 (95% CI 0.94–1.71)
from four studies reporting on the four outcomes (see Figure 5).
Discussion
The principal findings of our meta-analysis of prospective
cohort studies examining a potential association between FVL
or PGM are (1) we have shown that FVL is likely weakly
Table 1. Characteristics of included studies.
Study
City or
State,
Country
Gestational
Age at
Enrollment
Type of Thrombo-
philia and Prevalence,
%, (n/Total n)
Study Population
(Parity, Mean Age) Outcome
Quality
Assessment
(NOS)
Silver et al.,
2010 [40]
Maryland,
United States
14 wk or less PGM (+/2 or ++), 3.8%,
(156/4,167)
Mean age 25
(21–29) y
PET, SGA, PA, PL Selection, ****;
comparability, **;
outcome, ***;
Said et al.,
2010 [39]
Melbourne,
Australia
Prior to
22 wk
FVL (+/2 or ++), 5.4%,
(93/1,726) and PGM
(+/2 or ++), 2.4%,
(41/1,726)
100% nulliparous
women, mean age
29.264.8 y
PET, SGA, PA, PL selection, ****;
comparability, *;
outcome, **
Clark et al.,
2008 [33]
Glasgow, UK Range
7–16 wk
FVL(+/2 or ++), 6.6%,
(142/3,944)
45% primigravid
women, mean
age 2866y
PET, SGA, PL, Selection, ****;
comparability, **;
outcome, ***
Dudding et al.,
2008 [35]
Avon, UK Unclear FVL (+/2 or ++), 7.5%,
(587/7,869) and PGM
(+/2 or ++), 7.5%, (591/7,842)
44.3% nulliparous
women, 98.7%
,39 y
PET, SGA Selection, ****;
comparability, **;
outcome, *
Karakantza et al.,
2008 [36]
Patras, Greece Range
6–8 wk
FVL (+/2), 3.3%, (13/392)
and PGM (+/2), 3?1%,
(12/392)
39.8% nulliparous
women, 80.4% #35 y
PET, SGA, PA, PL Selection, ****;
comparability, 0;
outcome, **
Rodger et al.,
2007 [32]
Ottawa, Canada Under 16 wk FVL (+/2 or ++), 4.5%
(133/2,966) and PGM
(+/2 or ++), 2.1%,
(63/2,939)
34.9% nulliparous
women, mean age
31 y
PET, SGA, PA, PL Selection, ****;
comparability, *;
outcome, *
Lindqvist et al.,
2006 [37]
Malmo, Sweden Mean 12 wk FVL (+/2 or ++), 10.9%,
(270/2,480)
,45% nulliparous
women, mean age
29.264.7 y
PET, SGA, PA, PL Selection, ****;
comparability, **;
outcome, ***
Dizon-Townson
et al., 2005 [34]
Maryland,
United States
14 wk or less FVL (+/2 or ++), 2.7%,
(134/4,885)
30.7% primigravid
women, mean age
25.8 (65.6 y)
PET, SGA, PA, PL Selection, ****;
comparability, **;
outcome, ***
Salomon et al.,
2004 [31]
Tel Aviv, Israel Range
14–16 wk
FVL (+/2 or ++), 5.9%,
(38/643) and PGM
(+/2 or ++), 6.2%, (40/643)
100% nulliparous
women, mean age
2863.3 y
PET, SGA, PA Selection, ****;
comparability, *;
outcome, **
Murphy et al.,
2000 [38]
Dublin, Ireland Mean
14.260.26 wk
FVL (+/2), 2.7%, (16/588) 100% primigravid
women, mean age
2560.2 y
PET, SGA Selection, ***;
comparability, *;
outcome, **
Abbreviations: +/2, heterozygous carrier; ++, homozygous carrier; NOS, Newcastle Ottawa Scale for cohort studies (maximum n of starts: selection, 4; compatibility, 2;
outcome, 3); PA, placental abruption; PET, pre-eclampsia; PL, pregnancy loss.
doi:10.1371/journal.pmed.1000292.t001
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doi:10.1371/journal.pmed.1000292.g002
FVL and PGM and PMP Complications
PLoS Medicine | www.plosmedicine.org 6 June 2010 | Volume 7 | Issue 6 | e1000292associated with pregnancy loss and (2) we have shown that
neither FVL nor PGM are associated with pre-eclampsia or
b i r t ho fa nS G Ai n f a n t .F u r t h er research is required to
determine if FVL or PGM are associated with placental
abruption and whether PGM is associated with important
increases in pregnancy loss.
Pregnancy loss, especially recurrent or late pregnancy loss, is a
painful event for pregnant women and their families [3]. Despite
demonstrating that the odds of pregnancy loss in women with FVL
appears to be 52% higher as compared with women without FVL,
women with FVL should be reassured that the absolute event rate
for pregnancy loss is low (4.2%) and only appears slightly higher
Figure 3. Odds of placenta-mediated pregnancy complications in PGM (homozygous or heterozygous)-positive women.
doi:10.1371/journal.pmed.1000292.g003
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discussed below, this finding must be interpreted with caution
given the statistical and clinical heterogeneity in this analysis. If a
theoretical intervention was demonstrated to completely eliminate
this increased risk of pregnancy loss in women with FVL (i.e.,
100% relative risk reduction) it would result in a number needed to
treat (NNT) of 100. That is 100 women would require treatment
to prevent one pregnancy loss. Our findings are also in sharp
contrast to the initial case control study reports of a strong
association between FVL and pregnancy loss (e.g., ORs 4.9 with
FVL and stillbirth) [41] but consistent with later meta-analyses
[14].
We unfortunately had insufficient sample size to detect
important increases in the risk of pregnancy loss in women with
PGM. With a PGM prevalence of 2.9% in a sample size of 9,225,
we only have 80% power to detect an absolute increase of .4%
from the observed control group event rate of 3.6%. As such we
had limited power to detect important differences in absolute risk
of pregnancy loss (e.g., 1% or 2%) in women with PGM.
We found substantial statistical heterogeneity across studies
reporting pregnancy loss. It is well known that nonuniform
definitions of pregnancy loss across studies may create heteroge-
neity [42]. The likely explanations of the heterogeneity we
observed in our meta-analysis include the wide range of gestational
ages at enrollment (6 to 22 wk) in the component studies, the
inconsistent definition of pregnancy loss across studies, and
perhaps differences in parity in inclusion criteria between studies.
Pregnancy loss was defined as any loss (i.e., spontaneous
miscarriage or stillbirth) for most of the studies, but as spontaneous
miscarriage only for one study [38], and as stillbirth only for one
study [39]. Heterogeneity was significantly reduced when two
studies including only primiparous women [38,39] were removed
from meta-analysis.
Pre-eclampsia is the most important cause of premature delivery
with the resultant impact on fetal and neonatal morbidity and
mortality [2]. Our study failed to demonstrate an association
between the genetic thrombophilias and pre-eclampsia yet had
excellent power to detect these associations. We had over 90%
power to detect an absolute increase of 2% (from control 3.2% to
FVL 3.2%+2%=5.2%) in the rate of pre-eclampsia in women
with FVL and an increase of 3% (from control 3.4% to PGM
3.4%+3.0%=6.4%) in the rate of pre-eclampsia in women with
PGM, yet we did not detect any increased risk. This finding should
allow clinicians to provide reassurance to women with these
thrombophilias that they are not at significantly increased risk of
pre-eclampsia.
SGA often results in long-term effects in the developing child,
including developmental delay and poor school performance and,
as adults, children with SGA are significantly less likely to attain
higher academic and professional achievement [43]. A recently
Figure 4. FVL and composite placenta-mediated pregnancy complications.
doi:10.1371/journal.pmed.1000292.g004
Figure 5. PGM and composite placenta-mediated pregnancy complications.
doi:10.1371/journal.pmed.1000292.g005
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identified a significant association between FVL and SGA
(,10th percentile) in case control studies but identified evidence
of publication bias in these case control studies [44]. In their
analysis of retrospective and prospective cohort studies, there was
no evidence of association between FVL and SGA (,10th
percentile) (n=3 studies with 8,256 patients), and the authors
failed to identify any cohort studies examining an association
between PGM and SGA [44]. Our meta-analysis, which only
included prospective cohort studies, included more publications
and more patients (FVL, n=7 with .20,000 patients; PGM, n=5
with .17,000 patients) as we included abstracts and we contacted
the authors to obtain missing information, hence we can provide
more robust and precise estimates of association. Our study failed
to demonstrate an association between the genetic thrombophilias
and SGA yet had excellent power to detect an association. We had
over 90% power to detect an absolute increase of 3% (from control
7.4% to FVL 7.4%+3%=11.4%) in the rate of SGA (,10th
percentile) in women with FVL and an increase of 3% (from
control 5.4% to PGM 5.4%+3%=8.4%) in the rate of SGA
(,10th percentile) in women with PGM, yet we did not detect any
increased risk. This finding should allow clinicians to provide
reassurance to women with these thrombophilias that they are not
significantly more likely to give birth to an SGA child.
We had inadequate power to detect a doubling of risk of
placental abruption in women with FVL or women with PGM.
Unfortunately small sample sizes and low event rates limit
conclusions regarding an association between the inherited
thrombophilias, FVL or PGM, and placenta abruption. Further-
more, our analyses were limited by considerable statistical
heterogeneity likely resulting from variable definitions for placental
abruption.
The strengths of our study include: (1) the large number of
pregnancies collectively examined in prospective cohort studies,
which allows us to detect/exclude relatively small effects as
outlined above; (2) the inclusion of only prospective cohort studies,
which allows for more accurate directed data collection that
minimised outcome misclassification and likely improves com-
pleteness and accuracy of confounder data collection; (3)
prospective design that allows participant recruitment prior to
outcome determination thereby minimising selection bias; (4) we
suspect that prospective cohort studies are less likely than case
control studies to suffer from publication bias, as explained below;
and (5) the combination of prospective data without heterogeneity
from different parts of the western world increases the general-
izability of the study.
The limitations of our meta-analysis include: (1) prospective
cohort studies enrolling pregnant patients beyond the late first
trimester do not permit examination of early pregnancy events,
such as early pregnancy loss, prior to enrollment. Only one out of
seven studies reporting information on pregnancy loss exclusively
enrolled patients early in their first trimester of pregnancy [36].
Hence, we could not examine for an association with early
pregnancy loss. Only ‘‘conception’’ or prepregnancy prospective
cohorts would permit prospective examination of this issue; (2) we
had insufficient data and hence power to detect important
associations between PGM and pregnancy loss as well as FVL
or PGM and placental abruption; (3) there are insufficient
prospective cohort studies examining the less common and more
potent thrombophilias such as antithrombin, protein C, and
protein S deficiencies to elucidate associations between these
thrombophilias and placenta-mediated pregnancy complications.
Given the expense of biological assays for these thrombophilias,
the need for repeat confirmatory testing and false positives with
protein S in pregnancy it is unlikely that adequately powered
prospective cohort studies will be conducted to address the
question of an association between these thrombophilias and
placental-mediated pregnancy complications.
Our findings are in sharp contrast to the initial case control
study reports of a strong association between thrombophilia and
pre-eclampsia and SGA [43], and in contrast to later meta-
analyses of case control studies [13,15,16,41]. Several explanations
are possible for the discrepancy between case control and
prospective cohort studies in this area: (1) Publication bias: given
the tremendous expense and effort in completing prospective
cohort studies, negative studies are probably more likely to be
published than small inexpensive negative case control studies. If
this is the case, then proportionately more positive case control
studies may be published and lead to the discrepant findings,
indeed meta-analyses of case control studies in this area have
suggested publication bias [44,45]. The small number of cohort
studies included in our analysis of prospective cohort studies limits
the ability to detect publication bias in these prospective cohort
studies; (2) Interaction: it may be that thrombophilias do not cause
pre-eclampsia and SGA but synergise additional risk factors for
these complications (i.e., have an interactive effect). Given that
selection bias in case control studies may lead to more severe cases
being included than in cohort studies, interactive effects may be
more easily detected in case control studies and associations with
thrombophilia may be confounded by additional risk factors that
are more likely in selected case control studies.
The negative findings described in this publication are
important. The small step of previously describing an association
in case control studies has led a number of clinicians and opinion
leaders to take the large leap of accepting this relationship as being
causal and potentially treatable with anticoagulant interventions.
Many have adopted low molecular weight heparin as part of
routine care for women with a history of placenta-mediated
complications who have tested positive for a laboratory marker of
thrombophilia [1,46,47], and some have even adopted this
practice in women with prior placenta-mediated pregnancy
complications without thrombophilia, on the presumption that
they harbour yet to be discovered thrombophilia. However, recent
randomised trials have shown that low molecular weight heparin
in unselected women with prior recurrent early loss do not benefit
from low molecular weight heparin [48,49]. Further trials are
needed to determine if low molecular weight heparin will be of
benefit in thrombophilic women with prior placenta-mediated
pregnancy complications and in unselected women with the other
placenta-mediated pregnancy complications (late loss, SGA, pre-
eclampsia, abruption). Our findings highlight that in the absence
of ‘‘no intervention’’ controlled studies, adopting anticoagulant
prophylaxis to prevent these complications is premature and
should be considered experimental.
In summary, women with FVL appear to be at a small absolute
increased risk of late pregnancy loss. Women with FVL and PGM
appear not to be at increased risk of pre-eclampsia or birth of SGA
infants. Further research is required to determine if PGM is
associated with pregnancy loss and whether FVL or PGM are
associated with placental abruption. Adopting anticoagulant
prophylaxis to prevent these complications in thrombophilic
women is premature and should be considered experimental.
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Background. The death of a baby at any stage of
pregnancy is heartbreaking and, sadly, a quarter of women
lose their baby during pregnancy or birth. A pregnancy can
go wrong for many reasons but complications that are
caused by problems with the placenta affect more than one
in 20 pregnancies. The placenta is the organ that links the
mother to her baby. It is full of blood vessels that transfer
oxygen and nutrients from the mother to her baby and that
take carbon dioxide and waste products away from the baby.
If the placenta does not circulate blood efficiently between
the mother and baby (placental insufficiency), the result can
be pregnancy loss (spontaneous miscarriage or still birth),
pre-eclampsia (a sudden rise in blood pressure in late
pregnancy that is life-threatening for both mother and
baby), a small for gestational age pregnancy (the baby does
not grow properly during pregnancy), or placental abruption
(separation of the placenta from the wall of the womb, a
condition that deprives the baby of oxygen and nutrients
and can cause severe maternal blood loss).
Why Was This Study Done? One possible cause of
placental insufficiency is inherited thrombophilia, an
increased tendency to form blood clots that occurs in
more than 10% of people. The commonest inherited
thrombophilias are factor V Leiden (FVL) and prothrombin
gene mutation (PGM). Comparisons of the frequencies of
these thrombophilias in women who have had placenta-
mediated pregnancy complications with the frequencies in
women who have not had complications (‘‘retrospective case
control studies’’) have found an association between
thrombophilia and pregnancy complications. As a result,
doctors sometimes give heparin to women with
thrombophilia who have had a poor pregnancy outcome
to reduce blood clotting during subsequent pregnancies
(anticoagulant therapy). However, a better way to determine
whether thrombophilia and pregnancy problems are
associated is to recruit groups of women with and without
thrombophilia and follow them during pregnancy to see
whether they develop complications —‘‘prospective cohort
studies.’’ In this study, the researchers undertake a
systematic review (a search that uses predefined criteria to
identify all the research on a given topic) and meta-analysis
(a statistical method for combining the results of studies) of
prospective cohort studies to estimate the risk of placenta-
mediated pregnancy complications in women with FVL or
PGM.
What Did the Researchers Do and Find? The researchers
identified ten prospective cohort studies that examined the
association between FVL/PGM and placenta-mediated
pregnancy complications and that met their predefined
criteria. In their meta-analysis of these studies, they
estimated that the absolute risk of pregnancy loss in
women with FVL was 4.2% whereas the absolute risk of
pregnancy loss in women without FVL was 3.2%. In other
words, women with FVL had a 52% higher risk of pregnancy
loss than women without FVL (an odds ratio of 1.52). The
absolute increased risk, however, was 1%. There was no
significant association (a significant association is one that is
unlikely to have occurred by chance) between PGM and
pregnancy loss. Similarly, there was no significant association
between either of the thrombophilias and pre-eclampsia,
small for gestational age pregnancies, or placental abruption.
Finally, there was no significant association between either
FVL or PGM and the composite outcome of any placenta-
mediated pregnancy complication (pregnancy loss, pre-
eclampsia, small for gestational age, and placental abruption).
What Do These Findings Mean? These findings suggest
that women with FVL have a small absolute increased risk of
pregnancy loss but that neither FVL nor PGM increase a
woman’s risk of pre-eclampsia or of giving birth to a small for
gestational age infant. Although there seems to be no
increased risk of pregnancy loss with PGM, more research is
needed to confirm this finding and to confirm the lack of an
association between thrombophilia and placental abruption.
The researchers also warn that all these reassuring findings
should be treated cautiously because of variability between
the studies in how complications were defined. Importantly,
however, these findings suggest that the introduction of
anticoagulant therapies for women with thrombophilia
and a history of pregnancy complications on the basis of
retrospective case control studies might have been
premature. Anticoagulant therapy should be considered
experimental, therefore, until controlled trials of the
approach have been completed.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000292.
N Womenshealth.gov, a US Department of Health and
Human Services resource, provides information on preg-
nancy complications
N Tommy’s, a UK charity that funds scientific research into
the causes and prevention of miscarriage, premature birth,
and stillbirth, has information on problems in pregnancy
N The March of Dimes Foundation, a nonprofit organization
for pregnancy and baby health, also has information on
complications during pregnancy, including a fact sheet on
thrombophilias and pregnancy
N The US National Alliance for Thrombosis and Thrombo-
philia has detailed information on thrombophilia and an
article on the evolving story of thrombophilia and
pregnancy outcomes
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